✦ LIBER ✦

Cholinesterase inhibitors in the treatment of dementia

✍ Scribed by Maria Luisa Margallo-Lana; Clive Ballard; Chris Morris; David Kay; Stephen Tyrer; Brian Moore

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 36 KB
Volume: 18
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.809

No coin nor oath required. For personal study only.

✦ Synopsis

fact may be ascribed to a primarily biological origin of the disease, not correlated with other possible causative events (e.g. chronic somatic diseases). On the other hand, in patients with reactive depressive symptoms a higher prevalence of somatic dysfunction (e.g. number of diseases, Charlson Index, and premorbid functional status) has been detected and this may be responsible of a cascade of events leading to a lower cholesterol level through different mechanisms (chronic inflammation?).

REFERENCES

📜 SIMILAR VOLUMES

Feasibility of vascular dementia treatme

Feasibility of vascular dementia treatment with cholinesterase inhibitors

✍ Yansheng Li; John Stirling Meyer; MD Anwarul Haque; Munir H. Chowdhury; Peter Hi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

the range. Overall, it was found that the prevalence of substance misuse in the elderly in-patient population was lower than in the younger population, and a little lower than expected. There may be several reasons for this. Firstly, this study was not speci®cally designed for the elderly population

Treating the dementia of Iris with a cho

Treating the dementia of Iris with a cholinesterase inhibitor

✍ Robin Jacoby 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 19 KB

Treating the dementia of ‘Iris’ with a c

Treating the dementia of ‘Iris’ with a cholinesterase inhibitor

✍ Peter J. Connelly; Richard Athawes 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB

Cholinesterase inhibitors in dementia wi

Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis

✍ Mani Bhasin; Elise Rowan; Keith Edwards; Ian McKeith 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## Objective To compare efficacy of different cholinesterase inhibitors (ChEIs) for treating patients with dementia with Lewy bodies (DLB). ## Design Retrospective comparison of three independent clinical studies of ChEI treatment using donepezil, galantamine or rivastigmine in patie

Cholinesterase inhibitors in advanced De

Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?

✍ Sanjeet Pakrasi; Alan Thomas; Urs P. Mosimann; David A. Cousins; Debbie Lett; Da 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

## Abstract ## Introduction There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB. ## Method We conducted an open label trial w

Cerebral white matter changes and rate o

Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study

✍ M. E. Devine; J. A. S. Fonseca; R. W. H. Walker; T. Sikdar; T. Stevens; Z. Walke 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## Abstract ## Background Cerebral white matter changes (WMC) represent cerebrovascular disease (CVD) and are common in dementia. Cholinesterase inhibitors (ChEIs) are effective in Alzheimer's Disease (AD) with or without CVD, and in Dementia with Lewy Bodies (DLB). Predictors of treatment respons